Fig. 7

In vivo biodistribution and biosafety evaluation of MnGA Nanoparticles. a Blood-circulation curves of MnGA nanoparticles administrated intravenously (10 mg/kg, n = 4). The half-life period (τ1/2) of Mn was calculated to approximate 2.803 h. b Biodistributions of MnGA nanoparticles (%ID/g of Mn) in tumors, heart, liver, spleen, lung and kidney after intravenous administration (2, 8, 24 and 48 h, n = 4) c H&E staining of main organs such as the heart, liver, spleen, lung and kidney for biosafety evaluation of four groups in vivo. d–i Blood biochemical profile and blood routine tests on the 14th day in groups including Blank, NIR, MnGA and MnGA + NIR. Scale bar: c 100 μm